Pulmonary Hypertension
Nov 28, 2022
Nascent Advancements and Emerging Therapies in Chronic Pulmonary Hypertension Treatment Market
Chronic pulmonary hypertension (CPH) encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance, accounting for approximately 42 million cases in 7MM in 2021. As per DelveInsight’s analysis, the 7MM prevalence is expected to increase at a considerable CAGR of 0....
Read More...
-Agonist.png "Toll-like Receptors Agonist")
